Literature DB >> 15505879

Ovarian cancer in Europe: Cross-sectional trends in incidence and mortality in 28 countries, 1953-2000.

Freddie Bray1, Anja Helena Loos, Sandro Tognazzo, Carlo La Vecchia.   

Abstract

We have considered trends in incidence and mortality in 28 European countries using incidence data from successive volumes of Cancer Incidence in Five Continents and mortality from the WHO database. Countries with the highest rates in the early 1960s included the Nordic countries, Austria, Germany and the United Kingdom, but trends in these areas have tended to decline over recent calendar periods, particularly with regard to mortality. Southern European countries showed upward trends, at least until the early 1980s for France and Italy. Likewise, in most central and eastern European countries, ovarian cancer incidence and mortality rates were originally relatively low, but tended to rise over time. Falls in mortality, but not in incidence, over recent years were observed in the Czech Republic and Hungary. In several countries, mainly in northern Europe, trends were more favorable at younger age (25-49 years) than in the subsequent age groups. Thus, recent trends in ovarian cancer have led to a leveling of rates across various areas of the continent, although a 2.5-fold variation was still observed in the late 1990s between the highest mortality rate of 9.3/100,000 in Denmark and the lowest one of 3.6 in Portugal. These patterns should be viewed in the light of an observed reduction in parity, mainly in southern and eastern Europe, and the spread of oral contraceptive use, mainly in northern Europe, since these are the best recognized protective factors with regard to ovarian carcinogenesis. The declining mortality trends can also in part be ascribed to improvements in treatment. (c) 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2005        PMID: 15505879     DOI: 10.1002/ijc.20649

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  33 in total

1.  The influence of birth cohort and calendar period on global trends in ovarian cancer incidence.

Authors:  Citadel J Cabasag; Melina Arnold; John Butler; Manami Inoue; Britton Trabert; Penelope M Webb; Freddie Bray; Isabelle Soerjomataram
Journal:  Int J Cancer       Date:  2019-04-30       Impact factor: 7.396

Review 2.  Is human fecundity changing? A discussion of research and data gaps precluding us from having an answer.

Authors:  Melissa M Smarr; Katherine J Sapra; Alison Gemmill; Linda G Kahn; Lauren A Wise; Courtney D Lynch; Pam Factor-Litvak; Sunni L Mumford; Niels E Skakkebaek; Rémy Slama; Danelle T Lobdell; Joseph B Stanford; Tina Kold Jensen; Elizabeth Heger Boyle; Michael L Eisenberg; Paul J Turek; Rajeshwari Sundaram; Marie E Thoma; Germaine M Buck Louis
Journal:  Hum Reprod       Date:  2017-03-01       Impact factor: 6.918

3.  Report on trends of incidence (1970-2002) of and mortality (1952-2002) from cancer in Germany.

Authors:  Nikolaus Becker; Hans-Peter Altenburg; Christa Stegmaier; Hartwig Ziegler
Journal:  J Cancer Res Clin Oncol       Date:  2006-08-03       Impact factor: 4.553

4.  High IL-17-positive tumor immune cell infiltration is indicative for chemosensitivity of ovarian carcinoma.

Authors:  Raoul A Droeser; Uwe Güth; Serenella Eppenberger-Castori; Sylvia Stadlmann; Christian Hirt; Luigi Terracciano; Gad Singer
Journal:  J Cancer Res Clin Oncol       Date:  2013-04-28       Impact factor: 4.553

5.  Incidence and survival rates of ovarian cancer in low-income women in Sudan.

Authors:  Dafalla O Abuidris; Hsin-Yi Weng; Ahmed M Elhaj; Elgaylani Abdallah Eltayeb; Mohamed Elsanousi; Rehab S Ibnoof; Sulma I Mohammed
Journal:  Mol Clin Oncol       Date:  2016-10-31

6.  miRNA-574-3p inhibits metastasis and chemoresistance of epithelial ovarian cancer (EOC) by negatively regulating epidermal growth factor receptor (EGFR).

Authors:  Pengnan Zhang; Jie Zhu; Ya Zheng; Haiyan Zhang; Hong Sun; Shujun Gao
Journal:  Am J Transl Res       Date:  2019-07-15       Impact factor: 4.060

Review 7.  Primary and metastatic peritoneal surface malignancies.

Authors:  Delia Cortés-Guiral; Martin Hübner; Mohammad Alyami; Aditi Bhatt; Wim Ceelen; Olivier Glehen; Florian Lordick; Robert Ramsay; Olivia Sgarbura; Kurt Van Der Speeten; Kiran K Turaga; Manish Chand
Journal:  Nat Rev Dis Primers       Date:  2021-12-16       Impact factor: 52.329

8.  Role of Neoadjuvant Chemotherapy (NACT) Followed by Surgical Cytoreduction in Advanced Epithelial Ovarian Cancer.

Authors:  Sonia Batra; Himanshu Nayak; Kalpna S Dave
Journal:  J Obstet Gynaecol India       Date:  2012-03-07

9.  Clinical governance network for clinical audit to improve quality in epithelial ovarian cancer management.

Authors:  Vincenzo Dario Mandato; Martino Abrate; Pierandrea De Iaco; Debora Pirillo; Gino Ciarlini; Maurizio Leoni; Giuseppe Comerci; Alessandro Ventura; Bruno Lenzi; Andrea Amadori; Federica Rosati; Ruby Martinello; Rossana De Palma; Chiara Ventura; Laura Maria Beatrice Belotti; Debora Formisano; Giovanni Battista La Sala
Journal:  J Ovarian Res       Date:  2013-03-31       Impact factor: 4.234

10.  Clear cell histology as a poor prognostic factor for advanced epithelial ovarian cancer: a single institutional case series through central pathologic review.

Authors:  Morikazu Miyamoto; Masashi Takano; Tomoko Goto; Masafumi Kato; Naoki Sasaki; Hitoshi Tsuda; Kenichi Furuya
Journal:  J Gynecol Oncol       Date:  2013-01-08       Impact factor: 4.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.